PriceTracker GLP-1

FDA record · warning letter

FDA warning letter: Las Villas Health Care LLC dba Villas Health (Sep 9, 2025)

On Sep 9, 2025, FDA issued a warning letter to Las Villas Health Care LLC dba Villas Health of Coral Gables, FL under the subject "Unlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)". It names semaglutide. Open: no closeout letter published as of Oct 3, 2026.

Julian CaraulaniFounder, PriceTracker GLP-1FDA record read Oct 3
Status: Open: no closeout letter published as of Oct 3, 2026.

What FDA’s record states

FDA record for the warning letter to Las Villas Health Care LLC dba Villas Health
FieldWhat FDA’s record statesSource
RecipientLas Villas Health Care LLC dba Villas HealthFDA letter
LocationCoral Gables, FLFDA letter
Letter dateSep 9, 2025FDA letter
Posted by FDASep 16, 2025FDA index
Issuing officeCenter for Drug Evaluation and Research (CDER)FDA letter
SubjectUnlawful Sale of Unapproved and Misbranded Drugs to United States Consumers Over the Internet (Telehealth)FDA letter
MARCS-CMS number716504FDA letter
GLP-1 drugs namedSemaglutideFDA letter
Response letterNot published by FDAFDA letter
Closeout letterNot published by FDAFDA letter
“As described below, your claims concerning compounded semaglutide and sildenafil products are false or misleading under sections 502(a) and 502(bb) of the Federal Food, Drug, and Cosmetic Act (FDCA) [21 U.S.C. §§ 352(a) and 352(bb)], resulting in products being introduced or delivered for introduction into interstate commerce in violation of section 301(a) of the FDCA [21 U.S.C. § 331(a)].”FDA warning letter to Las Villas Health Care LLC dba Villas Health, Sep 9, 2025 · read the full letter on fda.gov ↗

What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.

Other GLP-1 letters FDA issued that week

Chengdu Brilliant Biopharmaceutical Co., Ltd.Sep 11, 2025motionpharmacy.comSep 10, 2025All American WellnessSep 9, 2025Amazing MedsSep 9, 2025ASN-LABSSep 9, 2025Bioverse, Inc. dba BioverseSep 9, 2025Body Good StudioSep 9, 2025Canada Med StopSep 9, 2025Cosmo Medical Spa dba Cosmo Med SpaSep 9, 2025CurexSep 9, 2025directmeds.com, Inc. dba DirectMedsSep 9, 2025Dr. Gater’s Weight Loss & WellnessSep 9, 2025

And 48 more in the full list.

Source

Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters